RxDoctor Payments Data

Sung Yong Bae, MD

Internal Medicine · Knoxville, TNNPI 1043443997

Payments from drug & device makers

$2,362in general payments, 2019–2025

Across 109 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$382
  • Nxstage Medical, Inc.$328
  • Amgen$297
  • Fresenius USA Marketing, Inc.$277
  • Travere Therapeutics, Inc.$134
  • Vifor Pharma, Inc.$115
  • plus $829 from 13 others

What the payments were for

  • Food & beverage$2,31698%
  • Education$462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,362 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$135,494
Medicare patients
247
Services billed
1,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide64$184,334
VeltassaPatiromer Calcium Sorbitex67$56,986
LokelmaSodium Zirconium Cyclosilicate67$46,053
AuryxiaFerric Citrate15$30,487
KerendiaFinerenone15$16,736
JardianceEmpagliflozin18$14,554
FarxigaDapagliflozin Propanediol26$13,993
Sevelamer Carbonate58$11,419
Irbesartan104$1,942
Calcitriol133$1,365
Midodrine Hcl19$1,357
Nifedipine ErNifedipine35$1,299
Cinacalcet Hcl13$1,204
Febuxostat13$944
Tamsulosin Hcl93$873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$277$184,33464 claims
AstraZenecaLokelma, Farxiga$382$60,04693 claims
Akebia Therapeutics IncAuryxia$43$30,48715 claims
BayerKerendia$92$16,73615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →